e-Posters - Pathology Week 2019
Ainash Altayeva
Almaty Oncology Center,Kazakhstan
The specificity of the Basal Cell Cocktail, P504S and ERG immunohistochemical markers in the diagnosis of prostate adenocarcinoma, experience of Almaty Oncology Center
Ainash Altayeva(Biography)
Ainash Altayeva obtained her MBBS and Masters in Pathology at Kazakh National Medical University.\r\nShe is interested to do Research in IHC studies of prostate cancer,Renal Pathology & Urinary Tract Pathology.She is working as a Faculty of Medicine,Head of the Pathology Department, Division of histology, cytology and embryology at Almaty Oncology Center,Kazakhstan.
Ainash Altayeva(Abstract)
Objective: Screening program for early detection of prostate cancer was carried out in Kazakhstan from 2014-2017. Total of 62,874 men were examined in Almaty with 794 patients (1.3%, 794/62,874) underwent prostate biopsy with 8-12 samples due to high PSAlevel.We evaluated expression of Basal Cell Cocktail, P504S (AMACR) and ERG (EPR3864) immunohistochemical markers to determine their specificity in the diagnosis of prostate adenocarcinoma. \r\nMethod: Prostate core needle biopsies from 794 patients (50-66 years) were evaluated using routine H&E sections and Ventana Basal Cell Cocktail (34βE12 + p63), P504S (AMACR) and ERG (EPR3864) immunohistochemical markers.\r\nResults: Prostate core needle biopsies of 794 patients were evaluated. Cases interpreted as HPIN or ASAP on routine H&E sections were evaluated with 2 step immunohistochemical study: a Ventana Basal Cell Cocktail marker (34βE12 + p63) was used for the 1st step and P504S (AMACR) and ERG (EPR3864) – for the 2nd step. Prostate adenocarcinoma was detected in 309 cases (39%, 309/794): Glisson score 6 (3+3) was detected in 44 (14.2%) cases, Glisson score 7 (3+4) - in 200 (64.7%), Glisson score 7 (4+3) - in 64 (20.7%) cases and Glisson score 8 (4+4) - in 1 case (0.4%). The use of the Basal Cell Cocktail and P504S markers showed the highest specificity (p≥0.95) for the diagnosis of prostate adenocarcinoma in comparison to the ERG marker (p≤0.45).\r\nConclusion: For differential diagnosis of prostate adenocarcinoma, we recommend use phased approach of Basal Cell Cocktail and P504S (AMACR) markers, since they are specific and highly sensitive. The ERG marker (EPR3864) is not recommended for routine use in the diagnosis of prostate adenocarcinoma, due to low reliability criteria.